Pure Global AI
NCT06097195Not yet recruiting

The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy

A Multi-centre, Prospective, Two-arm Randomised Controlled Trial to Determine the Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy
Neuronostics LtdClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Epilepsy
Drug/Device/Intervention
BioEP
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Neuronostics Ltd
Timeline & enrollment
Phase
N/A
Start date
Feb 01, 2024
End date
Jul 01, 2027
Enrollment
559 participants
Primary outcome

Time to working diagnosis (days).

Summary

Neuronostics plan a prospective multisite trial to determine the clinical utility of BioEP in
 the context of diagnostic decision making. Neuronostics will use findings from the trial to
 improve user experience of the Neuronostics platform (the tool which clinicians use to obtain
 a BioEP score from EEG and the aligned report). The data coming from the trial will also
 enable Neuronostics to iterate the BioEP algorithms and so improve future performance.

ICD-10 classifications
EpilepsyEpilepsy, unspecifiedOther epilepsyStatus epilepticusOther status epilepticus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06097195
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06097195 through Pure Global AI's free database. This phase not specified trial is sponsored by Neuronostics Ltd and is currently Not yet recruiting. The study focuses on Epilepsy. Target enrollment is 559 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.